168 related articles for article (PubMed ID: 30747749)
1. Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection.
Venkatesan V; Khanra S; Mandal K; Deepak MB
Clin Neuropharmacol; 2019; 42(2):64-65. PubMed ID: 30747749
[TBL] [Abstract][Full Text] [Related]
2. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
Novakovic V; Adel T; Peselow E; Lindenmayer JP
Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
[TBL] [Abstract][Full Text] [Related]
3. Delayed Onset Postinjection Delirium/Sedation Syndrome Associated With Olanzapine Pamoate: A Case Report.
Garg S; Gupta D; Rakesh K; Tikka SK
J Clin Psychopharmacol; 2019; 39(5):523-524. PubMed ID: 31433337
[No Abstract] [Full Text] [Related]
4. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
McDonnell DP; Detke HC; Bergstrom RF; Kothare P; Johnson J; Stickelmeyer M; Sanchez-Felix MV; Sorsaburu S; Mitchell MI
BMC Psychiatry; 2010 Jun; 10():45. PubMed ID: 20537130
[TBL] [Abstract][Full Text] [Related]
5. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.
Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP
BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Mohammad M; Alaoui-Ismaili Z; Baandrup L; Barzanji AF
Ugeskr Laeger; 2023 May; 185(19):. PubMed ID: 37170738
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.
Bushe CJ; Falk D; Anand E; Casillas M; Perrin E; Chhabra-Khanna R; Detke HC
BMC Psychiatry; 2015 Apr; 15():65. PubMed ID: 25886006
[TBL] [Abstract][Full Text] [Related]
8. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.
Luedecke D; Schöttle D; Karow A; Lambert M; Naber D
CNS Drugs; 2015 Jan; 29(1):41-6. PubMed ID: 25424243
[TBL] [Abstract][Full Text] [Related]
9. [Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].
Buts K; Van Hecke J
Tijdschr Psychiatr; 2014; 56(4):273-6. PubMed ID: 24807388
[TBL] [Abstract][Full Text] [Related]
10. Post-Injection Delirium/Sedation Syndrome: A Case Report and 2-Year Follow-Up.
Podgorná G; Albrecht J; Buday J; Mareš T; Le TH; Kališová L; Anders M
Am J Case Rep; 2022 Oct; 23():e937579. PubMed ID: 36245104
[TBL] [Abstract][Full Text] [Related]
11. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.
Detke HC; McDonnell DP; Brunner E; Zhao F; Sorsaburu S; Stefaniak VJ; Corya SA
BMC Psychiatry; 2010 Jun; 10():43. PubMed ID: 20537128
[TBL] [Abstract][Full Text] [Related]
12. Case series profile of olanzapine post-injection delirium/sedation syndrome.
Seebaluck J; Downes MA; Brown J; Harris K; Isoardi KZ; Chan BS
Br J Clin Pharmacol; 2023 Feb; 89(2):903-907. PubMed ID: 36349832
[TBL] [Abstract][Full Text] [Related]
13. Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?
Łukasik-Głębocka M; Sommerfeld K; Teżyk A; Panieński P; Żaba C; Zielińska-Psuja B
Basic Clin Pharmacol Toxicol; 2015 Sep; 117(3):213-4. PubMed ID: 25703610
[TBL] [Abstract][Full Text] [Related]
14. [Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year].
Potaufeu J; Langrée B; Drapier D; Burgot G; Marie N
Encephale; 2019 Jun; 45(3):232-238. PubMed ID: 30579574
[TBL] [Abstract][Full Text] [Related]
15. Postinjection Delirium/Sedation Syndrome with Olanzapine Depot Injection.
Sarangula SM; Mythri SV; Sanjay Y; Reddy MS
Indian J Psychol Med; 2016; 38(4):366-9. PubMed ID: 27570354
[TBL] [Abstract][Full Text] [Related]
16. A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.
Atkins S; Detke HC; McDonnell DP; Case MG; Wang S
BMC Psychiatry; 2014 Jan; 14():7. PubMed ID: 24423017
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine pamoate for the treatment of schizophrenia.
Naber D
Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine: a review of rapid and long-acting parenteral formulations.
Owen RT
Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591
[TBL] [Abstract][Full Text] [Related]
19. Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation.
Chartier F; Rouillon F; Berggren L; Jamonneau I; Falissard B; Llorca PM
Encephale; 2017 Aug; 43(4):303-310. PubMed ID: 28709669
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.
Samalin L; Garay R; Ameg A; Llorca PM
Expert Opin Drug Saf; 2016; 15(3):403-11. PubMed ID: 26761429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
